benefits to microdosing glp 1 GLP-1 Drugs Let's talk about “microdosing” GLP-1s

Diabetic rats treated for 42 d with a daily dose of 300 mg/kg of porcine skin gelatin showed their plasma glucose AUC reduced from 30 000 to 28 000 mg min/dl (1665 to 1554 mmol min/l), insulin levels increased 2-fold, active GLP-1 levels reduced from 15 to 135 pm and DPP4 activity reduced by half (Reference Huang, Hung and Jao48)

Per FDA guidance, GLP-1-based medications are generally approved for adults with a BMI over 30, or over 27 with a qualifying health condition such as type 2 diabetes, high blood pressure, or high cholesterol

Genetic variation in GLP-1 receptor (GLP1R), glucagon-dependent insulinotropic polypeptide receptor (GIPR), and melanocortin-4 receptor (MC4R) pathways may influence individual metabolic response and side-effect tolerance

Some patients feel tired during early dose adjustment

Indeed, a number of reports have included assessment of DPP-4 activity, albeit with conflicting results

Melasma update